In accordance with our findings revealing limited NECTIN‐4 expression in prostate cancer metastases, a thorough evaluation of NECTIN‐4 expression as a predictive marker is granted in EV‐treated patients with mCRPC. This evidence concerns the gene NECTIN4 and prostate cancer.